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obesity (BMI ≥25 kg/m²) contributed to 5·5% of total 
deaths, whereas underweight contributed to 0·7%, 
in their UK-based study population. The estimate for 
excess bodyweight with mortality is similar to that 
of the 2015 Global Burden of Disease Study,3 which 
estimated that, globally, overweight and obesity 
contributed to approximately 7·1% (95% uncertainty 
interval 4·9–9·6) of total deaths. PAF estimates are 
expected to vary across study populations according 
to the time period of data collection, socioeconomic 
development, and the ranking of common causes of 
mortality. Estimates of PAF for excess bodyweight with 
mortality will also continue to be a moving target as the 
population distribution of BMI shifts. Regardless, this 
metric provides a useful tool for health-care providers 
and stakeholders to appreciate the importance of 
overweight and obesity as an important driver of excess 
mortality. 
This study adds to the overwhelming evidence 
about the public health importance of the obesity 
epidemic to overall and cause-specific mortality. It also 
has important clinical and public health implications 
for obesity prevention, especially for the prevention 
of further increase in bodyweight and waist size 
among moderately overweight individuals. Although 
the debate might persist as to the precise point at 
which the association between continuous BMI with 
excess mortality becomes statistically significant, it is 
important to note that most people will gain weight 
throughout midlife, which is associated with increased 
subsequent risk of chronic diseases and mortality.5 
Many individuals with a BMI in the range of overweight 
(25·0–29·9 kg/m²) are already on a trajectory of gaining 
more weight that will transition them into the BMI 
range of obesity (≥30·0 kg/m²). Therefore, although 
the excess mortality associated with overweight 
is relatively small, it is important for overweight 
individuals to prevent further weight gain. Even among 
older populations, a plateau or decline in bodyweight 
often masks a trajectory of fat mass gain, offset by 
losses in lean body mass (ie, decreases in muscle tissue 
and bone density).6 Therefore, it is important for older 
individuals to prevent an increase in waist size, a marker 
of abdominal obesity, while minimising loss of muscle 
mass. Additional studies might shed more light on the 
role of body fat distributions and different fat depots 
in chronic disease morbidity and mortality. Meanwhile, 
current efforts need to be intensified to identify more 
effective and impactful strategies for prevention of 
weight gain and obesity-related comorbidities. 
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Oral health: a neglected aspect of diabetes care
Periodontitis and diabetes are well known to have a 
bidirectional association.1 Patients with uncontrolled 
diabetes are prone to periodontitis, probably due to 
their hyper-responsiveness to the oral dysbiosis and 
weakened healing processes, collectively causing perio-
dontal breakdown.2 Meanwhile, periodontitis associates 
with poor glycaemic control, leading to micro vascular 
complications.2 Furthermore, perio dontitis can also 
contribute to macrovascular complications through 
systemic inflam mation and its associated dyslipidaemia; 
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notably, periodontitis is a strong predictor of cardiorenal 
mortality in patients with diabetes.3 
In The Lancet Diabetes & Endocrinology, Francesco 
D’Aiuto and colleagues report the effects of periodontal 
treatment on glycaemic control of patients with 
type 2 diabetes in a carefully designed and performed 
randomised controlled trial.4 All patients had moderate-
to-severe periodontitis with signs of active disease; 
after initial extraction of unsalvageable teeth, patients 
were randomly assigned to receive intensive (IPT) or 
control (CPT) periodontal treatment. In addition to the 
exemplary periodontal outcomes achieved with the 
IPT, HbA1c (the primary outcome) and concentrations 
of glucose, C-reactive protein, and creatinine were 
significantly reduced compared with CPT at 12 months. 
Notably, in the primary adjusted analysis, HbA1c was 
reduced by 0·6 percentage points (95% CI 0·3 to 0·9; 
p<0·0001) with IPT compared with CPT, a decrease 
roughly equal to that of an additional glucose-lowering 
drug. Additionally, United Kingdom Prospective 
Diabetes Study 10 year cardiovascular disease risk 
and quality of life were both improved significantly 
in the IPT group compared with the CPT group. 
The overall findings suggest improved metabolic 
control and inflammation status, as well as improved 
endothelial and kidney function, following the intensive 
intervention. 
Periodontitis is associated with HbA1c levels not only 
in people with diabetes, but also in people without,5 
suggesting that the presence of periodontal disease 
might increase the risk of incident type 2 diabetes. 
In a 2017 study,6 men with moderate-to-severe 
periodontitis had a hazard ratio of 1·69 (95% CI 
1·06–2·69) for incident diabetes compared with men 
with no or mild periodontitis. An open question for 
future research is whether periodontal therapy could 
delay the onset of type 2 diabetes. 
Regarding the systemic effects of oral health, the role 
of another common infection has gained less attention 
than periodontitis. Apical periodontitis, commonly 
referred to as endodontic lesions, affects up to 61% 
of the European population, and approximately 5% 
of all teeth might display these pathological changes, 
which are easily detectable in radiographic images.7 An 
endodontic lesion is an inflammatory reaction at the 
apex of a tooth formed to capsulate the infection in the 
root canal. Although the inflammatory area is smaller 
than that found in periodontitis, endodontic lesions 
can also contribute to systemic inflammatory and 
immunological burden, and thereby cardiometabolic 
disorders,8 including diabetes.7 However, the scientific 
evidence on the role of endodontic lesions in general 
health is not yet conclusive.
Periodontitis and endodontic lesions are the two main 
reasons for tooth loss in adults. Importantly, retaining 
teeth and maintaining good oral health is valuable 
in itself. This benefit was suggested in the present 
study,4 which showed an improved quality of life due 
to the beneficial effects of IPT on working life, self-
confidence, and living conditions. Functioning teeth 
might be expected to help people to be able to enjoy a 
healthy diet, but the evidence on the effect of missing 
teeth on the quality of diet are conflicting.9 Crucially, 
however, missing teeth are also a valuable indicator of 
systemic health. In a population-based Finnish cohort 
who were followed up for 13 years,9 number of teeth 
was associated with several risk factors and increased 
hazards for incident diabetes, cardiovascular events, and 
all-cause mortality. The risk increased with the number 
of lost teeth and it was especially evident for advanced 
tooth loss (ie, nine or more missing teeth at baseline). 
Moreover, adding information on missing teeth to the 
list of established risk factors provided a significantly 
improved clinical prediction profile for diabetes and 
cardiovascular disease. In general health practice, 
missing teeth could be a useful indicator of oral health 
and suggest that a more detailed dental and medical 
evaluation is warranted. 
The results for IPT in the D’Aiuto and colleagues’ 
study4 are impressive in view of the reported local clinical 
measures and systemic inflammation bio markers. Simple 
cleaning and polishing of the teeth is not sufficient for 
the proper treatment of patients with periodontitis, 
which requires more aggressive and repeated removal of 
the microbial biofilm, including the plaque and calculus. 
Chronic periodontitis is treated mainly by mechanical 
means, and might require surgery.10 Most importantly, 
oral infections are always diagnosed and treated by 
a dentist (a specialised dentist if required) and the 
prescription of systemic antibiotics for bleeding gums by 
a physician is not appropriate. Naturally, the prevention 
of gingivitis and its conversion into periodontitis (and 
early diagnosis when periodontitis does occur) are 
primary goals. In susceptible individuals, such as people 
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with diabetes, a professional, biannual removal of biofilm 
would be an optimum choice.10
The treatment results achieved by D’Aiuto and 
collleagues4 could suggest protective effects from both 
microvascular and macrovascular complications, which 
are important causes of morbidity and mortality in people 
with diabetes. Hopefully follow-up of these patients will 
continue—or other longer-term studies will be done— 
in order to confirm the beneficial effects of intensive 
treatment of periodontitis in people with diabetes. 
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Psoriasis: a novel risk factor for type 2 diabetes
What do psoriasis, a common chronic skin disease, 
and type 2 diabetes, a disorder of insulin resistance, 
have in common? On the surface, not much it would 
appear. However, advances in medical informatics, 
immunology, and genetics have challenged old 
paradigms, breaking down artificial boundaries between 
the two diseases. Previously, psoriasis was classified as 
a disease limited to epidermal hyperproliferation.1 In 
1979, the observation that cyclosporin was effective 
for psoriasis in a patient who required the drug for 
organ transplantation challenged the long-held dogma 
that psoriasis was merely a disease of a dysregulated 
epidermis.2 Psoriasis is now believed to be a T-helper-17 
autoinflammatory disease, characterised by a genetic 
predisposition, with over 60 genes identified (HLA-Cw6 
being the most commonly implicated allele), and by 
chronic upregulation of innate and adaptive immune 
responses, antigen presentation (putative antigens 
being the keratinocyte-derived LL-37 and melanocyte 
derived ADAMTSL5), and increases in a variety of 
proinflammatory cytokines.3 
Although psoriasis and type 2 diabetes are 
phenotypically distinct, they share several common 
pathophysiological pathways.4 Genetically, CDKAL1 has 
been linked to both type 2 diabetes and psoriasis.5 More 
recently, novel susceptibility genes (PTPN22, ST6GAL1, 
JAZF1) were identified for psoriasis and type 2 diabetes 
in a Chinese population.6 Moreover, the inflammatory 
cytokines that are upregulated in psoriasis are increased 
in the skin, adipose tissue, and blood of patients in a 
manner that positively correlates with the severity of 
skin disease. For example, tumour necrosis factor α and 
interleukin 6 are known to promote insulin resistance. 
Other shared pathways include leptin, adiponectin, 
insulin-like growth factor-II, and vascular endothelial 
growth factor.7 Additional emerging pathways that are 
implicated include those of the glucagon-like peptide-1 
receptor and the incretin effect.8,9
Long before the genetics and pathophysiology 
of psoriasis and type 2 diabetes were defined, the 
co-occurrence of these diseases was first reported in the 
1890s.10 Modern epidemiological approaches have been 
applied to explore the relationship between psoriasis 
and type 2 diabetes. In 2009, the Nurses’ Health Study11 
demonstrated an increased incidence of type 2 diabetes 
in female nurses with psoriasis (n=1813), independent 
of risk factors such as BMI, smoking status, alcohol 
intake, and level of physical activity.12 A pooled analysis 
of the Nurses’ Health Study (women) and the Health 
Professionals’ Follow-Up Study (men) showed that 
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